AbbVie announced new late-breaking IMMerge Phase IIIb open-label study head-to-head data showing superior rates of skin clearance for Skyrizi (risankizumab)to Cosentyx (secukinumab) at week 52 in psoriasis. Particularly,… read more.
Genentech, a member of the Roche Group presented two-year data from Part 1 of its pivotal SUNFISH trial in people aged 2-25 years with Type 2 or 3… read more.
Swedish Orphan Biovitrum AB (publ) (Sobi™) and Selecta Biosciences, Inc. announced that the companies have entered into a strategic licensing agreement for the product candidate SEL 212. SEL… read more.
New real-world data showed Trulicity (dulaglutide), from Eli Lilly, had significantly higher adherence and longer persistence compared to weekly injections of semaglutide or exenatide (BCise pen) in people… read more.
Novo Nordisk announced results from two real-world studies: EXPERT, which confirms the efficacy Ozempic (once–weekly semaglutide) demonstrated in the SUSTAIN clinical trial programme, and PATHWAY, which supports recommendations… read more.
Sun Pharmaceutical Industries announced further evidence of the long-term use and cost-effectiveness of Ilumya (tildrakizumab-asmn) in moderate-to-severe plaque psoriasis. Long-term analyses of the phase III reSURFACE 1 and… read more.
Omeros Corporation announced that the results of its pivotal trial of OMS 721 (narsoplimab) in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) demonstrating that targeted… read more.
bluebird bio, Inc. announced that new data from its ongoing Phase 1/II HGB-206 study of investigational LentiGlobin gene therapy for adult and adolescent patients with sickle cell disease… read more.
NICE has published draft guidelines rejecting use of a combination drug therapy containing Sarclisa (isatuximab), from Sanofi, plus pomalidomide and dexamethasone (pom-dex), to treat multiple myeloma within the… read more.
Viela Bio announced that the FDA has approved Uplizna (inebilizumab-cdon) for the treatment of adult patients with neuromyelitis optica spectrum disorder (NMOSD) who are anti-AQP4 antibody positive as… read more.
Otsuka Pharmaceutical has announced positive top-line results from two, six-week, phase III clinical trials that evaluated the efficacy, safety and tolerability of oral EB 1020 (centanafadine), a novel… read more.
Impel NeuroPharma announced positive results from “STOP 301” (Safety and Tolerability of POD-DHE), the Company’s pivotal Phase III, open-label study of the safety and tolerability of INP 104… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
